Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

First Ten-Year Follow-Up Shows That Treatment With AVONEX® Leads To Long-Term Benefits In Early Multiple Sclerosis Patients
Biogen Idec (NASDAQ: BIIB) announced data results from the CHAMPIONS (Controlled High-Risk AVONEX® (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study). Based on the CHAMPS study, AVONEX was granted approval for use in patients who experienced their first clinical MS episode with MRI findings. The CHAMPIONS ten-year follow up showed that patients treated immediately after their first episode had significantly less chance of experiencing a second attack versus those patients with delayed treatment. These results at ten years also indicate that 80 percent of patients taking AVONEX were below an expanded disability status scale (EDSS) score of three. These data were presented as a poster at the Annual American Academy of Neurology (AAN) meeting.
generic viagra online
June Is Brain Injury Awareness Month In Canada
Brain injuries are the number one killer and disabler of people under the age of 45 in Canada. These injuries are
News of the day
Bevacizumab (Avastin(R)) Added To Common Chemotherapies Significantly Increases Tumour Shrinkage In HER2-negative Breast Cancer
Data presented at the American Society of Clinical Oncology (ASCO) 2009 meeting, in Orlando, Florida, show that bevacizumab (Avastin®) plus commonly used chemotherapies increases the chance of the patient living without the disease worsening by up to 36% compared to chemotherapies alone, in women receiving first-line therapy for advanced HER2-negative breast cancer. The Phase III RIBBON-1 study combined bevacizumab with chemotherapies, including capecitabine (Xeloda®), taxanes and anthracyclines and measured progression-free survival (PFS).1 No new safety signals for bevacizumab were observed in the study.
Public Health

University Of Kentucky's Markey Cancer Center Brings Advanced TomoTherapySM Treatment Technology To Brain And Body Radiosurgery Program

TomoTherapy Incorporated (NASDAQ: TOMO) announced that the University of Kentucky (UK) Chandler Medical Center"s Markey Cancer Center has commenced treating patients with the TomoTherapy® Hiò€¢Art® treatment system, a versatile, CT scanner-based device, which integrates image guidance for increased treatment accuracy and helical radiation therapy delivery for enhanced tumor targeting. The Hiò€¢Art treatment system was selected after a thorough review of technologies and will be extensively utilized in the Markey Cancer Center"s stereotactic body radiation therapy (SBRT) efforts, as part of its new Brain and Body Radiosurgery Program. Marcus E. Randall, M.D., professor and chair of the Department of Radiation Medicine at the UK College of Medicine, serves as director of the Brain and Body Radiosurgery Program. According to Dr. Randall, TomoTherapy technology was a natural choice. "We were looking for a platform that would permit exceptionally accurate treatments while allowing for reasonable throughput of patients," said Dr. Randall. "We considered all our options, including RapidArc™ and Cyberknife®, but we felt that the dose distributions from TomoTherapy were consistently superior to other platforms. The ability to do imaging at the time of treatment was also a unique advantage, so the decision actually became pretty simple." SBRT: A New Focus in Cancer Care SBRT is a noninvasive technique that precisely delivers high doses of radiation to a tumor, while minimizing damage to surrounding healthy tissues. In addition to growing evidence that this technique may be radiobiologically more effective for certain types of cancer cases, SBRT offers cancer centers the ability to treat more patients over a shorter, more convenient treatment schedule, requiring five or fewer treatments. Traditional radiation therapy, because a lower dose of radiation is delivered in each session, can require 20-40 treatments over a four to eight week period. Ronald McGarry, M.D., Ph.D., clinical associate professor and vice chair of the Department of Radiation Medicine at the UK College of Medicine, helped pioneer SBRT as a technique and has many years of experience with this advanced treatment approach. He believes the TomoTherapy platform offers specific advantages for cancer patients, including: the ability to reduce treatment times; track treatment progress via daily CT imaging and adapt the plan, if necessary; and potentially reduce treatment toxicity when critical organs are at risk. "The biggest gain to our department is the conformal radiation plans that helical intensity-modulated radiation therapy (IMRT) allows us to do," said Dr. McGarry. "We will also be pursuing adaptive radiation therapy using the CT guidance of TomoTherapy. Certainly, this is an advantage of the platform. For SBRT use, our main targets of interest for Tomo® will be spine, liver and prostate. Spine and prostate will be the subject of clinical trials in our department, and we are opening a spinal SBRT protocol which will largely be carried out using TomoTherapy technology." First TomoTherapy Hiò€¢Art Treatment System in Lexington The TomoTherapy Hiò€¢Art treatment system at Markey Cancer Center is the first to be installed in Lexington and the second in the state of Kentucky, which is ranked fourth nationwide in overall cancer incidence and has a significantly higher cancer mortality rate than the national average. "TomoTherapy is honored to have been chosen to improve cancer patient care in Kentucky," said Ralph Vaello, vice president of global sales for TomoTherapy Incorporated. "We are pleased to be playing an integral part in the Markey Cancer Center"s newly launched Brain and Body Radiosurgery Program. Endorsement by this program and by Dr. Randall and Dr. McGarry-pioneers in their field-further validates TomoTherapy as the platform of the future, designed to meet the widest range of advanced radiotherapy needs." About the Markey Cancer Center The Markey Cancer Center is a premier cancer research and patient care facility that utilizes the res of 28 departments, 8 colleges and 150 faculty throughout UK HealthCare to further the prevention, treatment and cure of cancer. To learn more, please visit here. TomoTherapy Incorporated


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009